Evidence map›Paper›PMID 35434594›Full record

ReviewMaterials today. Bio2022

Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects.

Mia Karam, Duaa Fahs, Batoul Maatouk, Brouna Safi, Ayad A Jaffa, Rami Mhanna

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Nanomedicine for Diagnosis and Treatment of Cardiac Fibrosis.International journal of nanomedicine · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mia KaramBiomedical Engineering Program, Maroun Semaan Faculty of Engineering and Architecture, Lebanon.
Duaa FahsBiomedical Engineering Program, Maroun Semaan Faculty of Engineering and Architecture, Lebanon.
Batoul MaatoukBiomedical Engineering Program, Maroun Semaan Faculty of Engineering and Architecture, Lebanon.
Brouna SafiDepartment of Chemical Engineering, Maroun Semaan Faculty of Engineering and Architecture, Lebanon.
Ayad A JaffaDepartment of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236, Beirut, Lebanon.
Rami MhannaBiomedical Engineering Program, Maroun Semaan Faculty of Engineering and Architecture, Lebanon.
American University of Beirut · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial infarction (MI) is the leading cause of morbidity and mortality worldwide. Despite extensive efforts to provide early diagnosis and adequate treatment regimens, detection of MI still faces major limitations and pathological MI complications continue to threaten the recovery of survivors. Polymeric nanoparticles (NPs) represent novel noninvasive drug delivery systems for the diagnosis and treatment of MI and subsequent prevention of fatal heart failure. In this review, we cover the recent advances in polymeric NP-based diagnostic and therapeutic approaches for MI and their application as multifunctional theranostic tools. We also discuss the

Indexed as

DiagnosisMyocardial infarctionPolymeric nanoparticlesTable of contentsTheranosticsTreatment

Identifiers

PMID35434594
PMCPMC9006854
OpenAlexW4224236004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.